Nimotuzumab treatment of malignant gliomas

Udo Bode, Maura Massimino, Ferdinand Bach, Martina Zimmermann, Elena Khuhlaeva, Manfred Westphal, Gudrun Fleischhack

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Introduction: In spite of new alkylating medication and recently accumulated knowledge about genomics, the prognosis of malignant gliomas remains poor. The introduction of single substances interfering with tumour proliferation dynamics has been disappointing and the lessons learned indicate that a complicated network of proliferation needs time consuming, in-depth analysis in order to more specifically treat now distinguishable subgroups of a disease, which too long was thought of as a uniform entity. Areas covered: The clinical trials using the EGFR antibody nimotuzumab in the treatment of malignant gliomas are reviewed. Pending conformation in future studies the antibody might be part of the treatment of MGMT-negative, EGFR-amplified, not completely resected gliomas of adulthood and juvenile DIPG (pontine gliomas). Upcoming genomic results of the different tumour entities may suggest certain combination partners of the antibody. Recent studies of nimotuzumab indicate the reason for the lack of toxicity, which is the most attractive argument for its clinical use besides modest efficacy. Expert opinion: We await the final results on the use of the antibody together with vinorelbine and radiation therapy for the therapy of DIPG. Adult patients with MGMT-negative, EGFR amplified, not totally resected GBM may also profit from this combination therapy. TK-inhibitors combined with the antibody and irradiation may be an option for a therapeutic trial in paediatric patients.

Original languageEnglish
Pages (from-to)1649-1659
Number of pages11
JournalExpert Opinion on Biological Therapy
Volume12
Issue number12
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Glioma
Antibodies
Tumors
Therapeutics
Pediatrics
Radiotherapy
Expert Testimony
Genomics
Toxicity
Conformations
Neoplasms
Profitability
nimotuzumab
Clinical Trials
Irradiation

Keywords

  • EGFR-antagonists
  • EGFR-antibodies
  • Glioma
  • Malignant glioma
  • Nimotuzumab
  • Paediatric brain tumours
  • Pontine glioma

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

Bode, U., Massimino, M., Bach, F., Zimmermann, M., Khuhlaeva, E., Westphal, M., & Fleischhack, G. (2012). Nimotuzumab treatment of malignant gliomas. Expert Opinion on Biological Therapy, 12(12), 1649-1659. https://doi.org/10.1517/14712598.2012.733367

Nimotuzumab treatment of malignant gliomas. / Bode, Udo; Massimino, Maura; Bach, Ferdinand; Zimmermann, Martina; Khuhlaeva, Elena; Westphal, Manfred; Fleischhack, Gudrun.

In: Expert Opinion on Biological Therapy, Vol. 12, No. 12, 12.2012, p. 1649-1659.

Research output: Contribution to journalArticle

Bode, U, Massimino, M, Bach, F, Zimmermann, M, Khuhlaeva, E, Westphal, M & Fleischhack, G 2012, 'Nimotuzumab treatment of malignant gliomas', Expert Opinion on Biological Therapy, vol. 12, no. 12, pp. 1649-1659. https://doi.org/10.1517/14712598.2012.733367
Bode U, Massimino M, Bach F, Zimmermann M, Khuhlaeva E, Westphal M et al. Nimotuzumab treatment of malignant gliomas. Expert Opinion on Biological Therapy. 2012 Dec;12(12):1649-1659. https://doi.org/10.1517/14712598.2012.733367
Bode, Udo ; Massimino, Maura ; Bach, Ferdinand ; Zimmermann, Martina ; Khuhlaeva, Elena ; Westphal, Manfred ; Fleischhack, Gudrun. / Nimotuzumab treatment of malignant gliomas. In: Expert Opinion on Biological Therapy. 2012 ; Vol. 12, No. 12. pp. 1649-1659.
@article{10ac2633bfc240dd8781bf6b38e6d93d,
title = "Nimotuzumab treatment of malignant gliomas",
abstract = "Introduction: In spite of new alkylating medication and recently accumulated knowledge about genomics, the prognosis of malignant gliomas remains poor. The introduction of single substances interfering with tumour proliferation dynamics has been disappointing and the lessons learned indicate that a complicated network of proliferation needs time consuming, in-depth analysis in order to more specifically treat now distinguishable subgroups of a disease, which too long was thought of as a uniform entity. Areas covered: The clinical trials using the EGFR antibody nimotuzumab in the treatment of malignant gliomas are reviewed. Pending conformation in future studies the antibody might be part of the treatment of MGMT-negative, EGFR-amplified, not completely resected gliomas of adulthood and juvenile DIPG (pontine gliomas). Upcoming genomic results of the different tumour entities may suggest certain combination partners of the antibody. Recent studies of nimotuzumab indicate the reason for the lack of toxicity, which is the most attractive argument for its clinical use besides modest efficacy. Expert opinion: We await the final results on the use of the antibody together with vinorelbine and radiation therapy for the therapy of DIPG. Adult patients with MGMT-negative, EGFR amplified, not totally resected GBM may also profit from this combination therapy. TK-inhibitors combined with the antibody and irradiation may be an option for a therapeutic trial in paediatric patients.",
keywords = "EGFR-antagonists, EGFR-antibodies, Glioma, Malignant glioma, Nimotuzumab, Paediatric brain tumours, Pontine glioma",
author = "Udo Bode and Maura Massimino and Ferdinand Bach and Martina Zimmermann and Elena Khuhlaeva and Manfred Westphal and Gudrun Fleischhack",
year = "2012",
month = "12",
doi = "10.1517/14712598.2012.733367",
language = "English",
volume = "12",
pages = "1649--1659",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",
number = "12",

}

TY - JOUR

T1 - Nimotuzumab treatment of malignant gliomas

AU - Bode, Udo

AU - Massimino, Maura

AU - Bach, Ferdinand

AU - Zimmermann, Martina

AU - Khuhlaeva, Elena

AU - Westphal, Manfred

AU - Fleischhack, Gudrun

PY - 2012/12

Y1 - 2012/12

N2 - Introduction: In spite of new alkylating medication and recently accumulated knowledge about genomics, the prognosis of malignant gliomas remains poor. The introduction of single substances interfering with tumour proliferation dynamics has been disappointing and the lessons learned indicate that a complicated network of proliferation needs time consuming, in-depth analysis in order to more specifically treat now distinguishable subgroups of a disease, which too long was thought of as a uniform entity. Areas covered: The clinical trials using the EGFR antibody nimotuzumab in the treatment of malignant gliomas are reviewed. Pending conformation in future studies the antibody might be part of the treatment of MGMT-negative, EGFR-amplified, not completely resected gliomas of adulthood and juvenile DIPG (pontine gliomas). Upcoming genomic results of the different tumour entities may suggest certain combination partners of the antibody. Recent studies of nimotuzumab indicate the reason for the lack of toxicity, which is the most attractive argument for its clinical use besides modest efficacy. Expert opinion: We await the final results on the use of the antibody together with vinorelbine and radiation therapy for the therapy of DIPG. Adult patients with MGMT-negative, EGFR amplified, not totally resected GBM may also profit from this combination therapy. TK-inhibitors combined with the antibody and irradiation may be an option for a therapeutic trial in paediatric patients.

AB - Introduction: In spite of new alkylating medication and recently accumulated knowledge about genomics, the prognosis of malignant gliomas remains poor. The introduction of single substances interfering with tumour proliferation dynamics has been disappointing and the lessons learned indicate that a complicated network of proliferation needs time consuming, in-depth analysis in order to more specifically treat now distinguishable subgroups of a disease, which too long was thought of as a uniform entity. Areas covered: The clinical trials using the EGFR antibody nimotuzumab in the treatment of malignant gliomas are reviewed. Pending conformation in future studies the antibody might be part of the treatment of MGMT-negative, EGFR-amplified, not completely resected gliomas of adulthood and juvenile DIPG (pontine gliomas). Upcoming genomic results of the different tumour entities may suggest certain combination partners of the antibody. Recent studies of nimotuzumab indicate the reason for the lack of toxicity, which is the most attractive argument for its clinical use besides modest efficacy. Expert opinion: We await the final results on the use of the antibody together with vinorelbine and radiation therapy for the therapy of DIPG. Adult patients with MGMT-negative, EGFR amplified, not totally resected GBM may also profit from this combination therapy. TK-inhibitors combined with the antibody and irradiation may be an option for a therapeutic trial in paediatric patients.

KW - EGFR-antagonists

KW - EGFR-antibodies

KW - Glioma

KW - Malignant glioma

KW - Nimotuzumab

KW - Paediatric brain tumours

KW - Pontine glioma

UR - http://www.scopus.com/inward/record.url?scp=84869449735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869449735&partnerID=8YFLogxK

U2 - 10.1517/14712598.2012.733367

DO - 10.1517/14712598.2012.733367

M3 - Article

VL - 12

SP - 1649

EP - 1659

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 12

ER -